Raij L, Chiou X C, Owens R, Wrigley B
Am J Med. 1985 Sep 27;79(3C):37-41. doi: 10.1016/0002-9343(85)90078-6.
Systemic hypertension does not always reflect concomitant glomerular hypertension. At similar levels of systemic hypertension, glomerular injury occurs only in kidneys that lack protective preglomerular vasoconstriction, which results in glomerular hypertension. indeed, glomerular hypertension and glomerular injury do not develop in rats with spontaneous hypertension that have effective preglomerular vasoconstriction. In the experiments reported herein, the normal adaptive response (afferent arteriolar dilation) to a reduction of one and five-sixths of the renal mass in rats with spontaneous hypertension was examined to ascertain whether that response would expose the remaining nephrons to the injurious effects of high perfusion pressure. In addition, the efficacies of two different antihypertensive regimens were compared. Rats with spontaneous hypertension received either no therapy, or a combination of hydralazine, reserpine, and hydrochlorothiazide, or the angiotensin converting enzyme inhibitor enalapril. Three weeks after ablation of one and five-sixths of the renal mass, blood pressure, glomerular filtration rate, urinary protein excretion, and histologic injury scores for mesangial expansion and glomerulosclerosis were determined. Untreated rats with hypertension had severe glomerulosclerosis and mesangial expansion. Both antihypertensive regimens normalized systemic blood pressure and reduced glomerulosclerosis. However, enalapril was more effective than the combination of hydralazine, reserpine, and hydrochlorothiazide in reducing the exaggerated glomerular filtration rate (0.52 +/- 0.40 versus 0.82 +/- 0.10 ml per minute; p less than 0.05), the injury score for mesangial expansion (79 versus 103; p less than 0.05), and the degree of proteinuria (32 +/- 4 versus 42 +/- 3 mg per 24 hours; p less than 0.05). Persistence of hyperfiltration accompanied by increased mesangial expansion, may lead to progression of glomerular damage despite "adequate" control of systemic hypertension, as observed in rats treated with a combination of hydralazine, reserpine, and hydrochlorothiazide.
系统性高血压并不总是反映出同时存在的肾小球高血压。在相似的系统性高血压水平下,肾小球损伤仅发生在缺乏保护性肾小体前血管收缩的肾脏中,这会导致肾小球高血压。实际上,在具有有效的肾小体前血管收缩的自发性高血压大鼠中,并不会发生肾小球高血压和肾小球损伤。在本文所报道的实验中,研究了自发性高血压大鼠肾质量减少六分之一和六分之五时的正常适应性反应(入球小动脉扩张),以确定该反应是否会使剩余的肾单位暴露于高灌注压力的有害影响之下。此外,还比较了两种不同降压方案的疗效。自发性高血压大鼠分别接受无治疗、肼屈嗪、利血平和氢氯噻嗪联合治疗或血管紧张素转换酶抑制剂依那普利治疗。在切除六分之一和六分之五的肾质量三周后,测定血压、肾小球滤过率、尿蛋白排泄以及系膜扩张和肾小球硬化的组织学损伤评分。未经治疗的高血压大鼠出现严重的肾小球硬化和系膜扩张。两种降压方案均使系统性血压恢复正常并减轻了肾小球硬化。然而,依那普利在降低过高的肾小球滤过率(每分钟0.52±0.40对0.82±0.10毫升;p<0.05)、系膜扩张损伤评分(79对103;p<0.05)和蛋白尿程度(每24小时32±4对42±3毫克;p<0.05)方面比肼屈嗪、利血平和氢氯噻嗪联合治疗更有效。如在接受肼屈嗪、利血平和氢氯噻嗪联合治疗的大鼠中所观察到的,尽管系统性高血压得到了“充分”控制,但高滤过的持续存在伴随着系膜扩张的增加,可能会导致肾小球损伤的进展。